The short answer
Beyond off-target toxicity and on-target excess, there is a third category: effects that follow from what a treatment achieves rather than from the treatment itself. Any intervention producing the same physiological change at the same speed would be expected to produce them.
Key facts
- Category 1
- Off-target toxicity
- Category 2
- On-target effect, exceeded
- Category 3
- Consequence of the achievement
- Example
- Gallstones from rapid weight loss
- Example
- Retinopathy from rapid HbA1c fall
- Test
- Would diet or surgery do the same?
Why two categories were not enough
Adverse effects are usually divided into off-target (unrelated to the intended action) and on-target, the intended action carried too far. Neither describes gallstones after rapid weight loss. That is not an unrelated toxicity, and it is not the pharmacology exceeded; it is a consequence of the weight loss itself, which was the goal.
The test that separates the third category
Ask whether a completely different intervention achieving the same result would produce the same effect. Rapid weight loss by dieting or surgery raises gallstone risk, so the answer is yes. Rapid glycaemic improvement by any means is associated with early retinopathy worsening, so again yes. Where the answer is yes, the drug is the vehicle rather than the agent.
Research material referenced
Retatrutide 10mg, third-party HPLC tested
Why this changes how a signal should be read
An effect in this category cannot be engineered away by improving the molecule, and it does not distinguish between compounds achieving the same result. It also scales with effectiveness. A drug that produces a larger, faster change encounters it more, which makes better drugs look worse on the measure.
The two clear instances on this site
Gallbladder events, where rapid weight reduction is an established gallstone risk factor independent of how the weight was lost. And retinopathy, where the 2018 SUSTAIN analysis frames risk through the reduction in glycated haemoglobin rather than through the compound. Both are documented, and both are routinely reported as drug effects.
Where the categories overlap
They are not always clean. The gallbladder case has a second, drug-specific pathway (suppression of cholecystokinin reducing gallbladder emptying) running alongside the weight loss pathway. So an effect can belong to two categories at once, which is why the question is what proportion rather than which box.
And the fourth possibility, for completeness
That the association belongs to neither the drug nor its achievement but to the condition being treated. This is confounding by indication, as the Danish periconceptional cohort demonstrated when a preterm birth association appeared in the diabetes indication and not in weight management. There are four ways to be wrong about causation, and reporting usually considers one.
Quick reference
| Category | Arises from | Engineered away? |
|---|---|---|
| Off-target | Something other than the mechanism | In principle, by selectivity |
| On-target, exceeded | The mechanism itself | Not without weakening the drug |
| Consequence of achievement | The result, however produced | No, intrinsic to the goal |
| Confounding by indication | The underlying condition | Not a drug effect at all |
Frequently asked questions
How is this different from an on-target effect?
An on-target effect is the mechanism taken too far. This follows from the result achieved, and would occur with any intervention producing the same change.
What is the test?
Would diet or surgery achieving the same change at the same speed produce it too? If yes, the drug is the vehicle rather than the agent.
Can an effect belong to more than one category?
Yes. Gallbladder events have both a rapid-weight-loss pathway and a drug-specific one through cholecystokinin suppression.
Continue researching
Related guides and reference material.
Primary sources & clinical trials
Published papers, trial registrations, regulator pages and company announcements. Links open the original.
- PubMedVilsbøll T et al., Semaglutide, reduction in glycated haemoglobin and the risk of diabetic retinopathy. Diabetes Obes Metab 2018 (PMID 29178519)pubmed.ncbi.nlm.nih.gov
- PubMedRehfeld JF et al., Cholecystokinin secretion is suppressed by glucagon-like peptide-1. Scand J Gastroenterol 2018 (PMID 30449207)pubmed.ncbi.nlm.nih.gov
- PubMedHviid KVR et al., Periconceptional GLP-1 receptor agonist exposure and obstetric outcomes. Hum Reprod Open 2026 (PMID 41852577)pubmed.ncbi.nlm.nih.gov
Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).
Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.
More GLP-1 & Incretin Science articles
- Comparing Things That Were Never ComparedWhen no head-to-head exists, a network meta-analysis links treatments through shared comparators. It rests on an assumption worth understanding.
- A Second Entrant to Tirzepatide's MechanismVK2735 is a GIP/GLP-1 dual agonist - the same receptor pair as tirzepatide. Its Phase 2 VENTURE study ran 13 weeks, too short to compare with 72-week data.
- A GLP-1/Glucagon Dual Aimed at the LiverPemvidutide pairs GLP-1 with glucagon receptor agonism and was studied for 24 weeks in metabolic dysfunction-associated steatotic liver disease.
- An Amylin Analogue Built to Stand AlonePetrelintide is described as a potent, stable, long-acting human amylin analogue - engineered by Zealand Pharma with Boehringer Ingelheim.
- The Amyloid Problem at the Centre of Amylin DesignHuman amylin forms amyloid fibrils. Every amylin medicine is a solution to that, and the two available solutions are instructively different.